23andMe has recently unveiled an initiative aimed at offering deeper insights into the risk of developing breast cancer. The company’s new genetic reports bring forth a new approach to cancer risk prediction, particularly focusing on breast, colorectal, and prostate cancer.
Recent studies have underscored a concerning trend: a notable increase in cancer diagnoses among younger individuals. Federal data from the US indicates a surge of nearly 13% in cancer diagnosis rates among people under 50. Against this backdrop, the significance of early detection in combating cancer cannot be overstated.
The unveiling of these new genetic reports from 23andMe could present a significant advancement in cancer risk assessment. Leveraging advanced statistical models known as polygenic risk scores (PRS), developed through extensive research and analysis, 23andMe’s reports offer customers invaluable insights into their likelihood of developing breast cancer, among other common forms of cancer.
“Using these reports to understand your likelihood to develop common cancers is an important step toward further integrating genetics into healthcare,” said Noura Abul-Husn, Vice President of Genomic Health at 23andMe. “Today, there is increasing evidence and support for the use of PRS in personalized disease prevention, and certain medical specialties — including oncology — have already begun to adopt this to inform clinical decision-making. These new reports will help customers better understand their overall likelihood for developing these diseases, and enable them to work with their healthcare providers to implement prevention plans.”
It’s important to note that while these reports may mark a significant advancement, they come with limitations. For instance, availability of breast cancer and prostate cancer PRS reports is contingent upon self-reported birth sex. Moreover, the reports do not diagnose conditions nor provide a comprehensive overview of an individual’s risk. However, they serve as a crucial starting point in initiating proactive healthcare measures.
